As of February 2011, Wörwag Pharma has successfully launched its first product on the Brazilian market. – MILGAMMA 150.

We have a nationwide coverage with major metropolitan areas (Sao Paulo, Rio de Janeiro and the capital Brasilia) being the focus. The target group for our medical detailing activities are prescribing physicians. The product is positioned as a unique form of Vitamin B1 with neuro-protective benefits and high levels resorption.

With the indication of neuropathic pain, we are mainly visiting Endocrinologists and Cardiologist. The second indication of neurological inflammatory and compressive pain is presented towards Orthopaedists, General Practitioners and Neurologists.

In addition to raising scientific awareness about Benfotiamine in the medical community, positioning the product as an acute treatment for neuropathic pain and its preventative effects are mid-term goals.

In order to achieve this, various road shows, speaker trainer programmes and a scientific Satellite Launch Symposium are part of the launch campaign for 2011.

We are convinced that this launch campaign is only the first step in a successful and long-term roll out of the Wörwag Pharma business in Brazil and across South America.